Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial
Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial
复制标题
DOI：
10.1111/bdi.12487
复制
发表时间：
2017-05-01
影响因子：
5.4
通讯作者：
Mann, J. John
中科院分区：
文献类型：
--
作者：
Grunebaum, Michael F.;Ellis, Steven P.;Mann, J. John
目的评价亚麻醉剂量氯胺酮与咪达唑仑治疗双相抑郁症自杀意念的可行性及效果。研究了神经认知、血液和唾液生物标志物。方法16例自杀意念量表评分为4分的双相抑郁症患者随机服用氯胺酮（0.5mg/kg）或咪达唑仑（0.02mg/kg）。在24小时内维持目前的药物治疗，不包括苯二氮卓类药物。主要临床结果为输注后第1天的SSI评分。结果结果支持可行性。氯胺酮输注后SSI的平均降幅几乎比咪达唑仑输注后大6点，尽管这没有统计学意义（估计值=5.84，SE=3.01, t=1.94， P= 0.074, 95%可信区间（[CI）]=-0.65 ~ 12.31）。治疗产生反应所需的数量（SSI）
ObjectivesTo evaluate feasibility and effects of a sub-anesthetic infusion dose of ketamine versus midazolam on suicidal ideation in bipolar depression. Neurocognitive, blood and saliva biomarkers were explored.MethodsSixteen participants with bipolar depression and a Scale for Suicidal Ideation (SSI) score of 4 were randomized to ketamine (0.5mg/kg) or midazolam (0.02mg/kg). Current pharmacotherapy was maintained excluding benzodiazepines within 24hours. The primary clinical outcome was SSI score on day 1 post-infusion.ResultsResults supported feasibility. Mean reduction of SSI after ketamine infusion was almost 6 points greater than after midazolam, although this was not statistically significant (estimate=5.84, SE=3.01, t=1.94, P=.074, 95% confidence interval ([CI)]=-0.65 to 12.31). The number needed to treat for response (SSI